MTM Laboratories, headquartered in Heidelberg, Germany, with subsidiaries in the United States, France, Italy, and Spain, markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on MTM's proprietary E6H4(TM) antibody clone, specifically developed for immunochemistry applications in cervical cytology preparations and tissue sections. The company's technology platforms target the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a, and the kits are manufactured under GMP standards to ensure reproducible quality and results.